CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
暂无分享,去创建一个
Pachai Natarajan | Angelia Viley | Susan Moir | Harry L. Malech | Linhong Li | C. Allen | M. Peshwa | D. Kuhns | S. Moir | U. Choi | H. Malech | Xiaolin Wu | L. Kardava | K. Zarember | Xiaolin Wu | Jessica Chu | Suk See De Ravin | Linhong Li | Ling Su | Uimook Choi | Janet Lee | Sherry Koontz | Colin Sweeney | Angelia M. Viley | Cornell Allen | Narda Theobald-Whiting | Mary Garofalo | Lela Kardava | Douglas Kuhns | Kol A. Zarember | Madhusudan V. Peshwa | Mary Garofalo | J. Chu | S. Koontz | L. Su | C. Sweeney | Janet Lee | P. Natarajan | Narda Theobald-Whiting | S. De Ravin | Ling Su
[1] J. Keith Joung,et al. 731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .
[2] S. Holland,et al. Residual NADPH oxidase and survival in chronic granulomatous disease. , 2010, The New England journal of medicine.
[3] A. Thrasher,et al. Patching up hematopoietic stem cells , 2015, Nature Biotechnology.
[4] C. von Kalle,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.
[5] M. van der Burg,et al. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.
[6] P. Disterer,et al. Use of internally nuclease‐protected single‐strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells following gene editing , 2009, The journal of gene medicine.
[7] H. Malech,et al. Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency , 2015, Transfusion.
[8] Kathryn L. Parsley,et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] D. Trono,et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] J. Doudna,et al. The use of CRISPR/Cas9, ZFNs, TALENs in generating site specific genome alterations , 2014 .
[11] R. Sitia,et al. AQP8 transports NOX2‐generated H2O2 across the plasma membrane to promote signaling in B cells , 2016, Journal of leukocyte biology.
[12] L. Notarangelo,et al. Immune deficiencies, infection, and systemic immune disordersComparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency , 2014 .
[13] Lei Zhang,et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.
[14] J. Doudna,et al. Methods in Enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specific genome alterations. Preface. , 2014, Methods in enzymology.
[15] H. Nakauchi,et al. An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils , 2015, Molecular therapy. Methods & clinical development.
[16] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[17] Shondra M. Pruett-Miller,et al. Gene editing using ssODNs with engineered endonucleases. , 2015, Methods in molecular biology.
[18] T. Chun,et al. Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells. , 2012, Blood.
[19] J. Joung,et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition , 2015, Nature Biotechnology.
[20] Luca Biasco,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.
[21] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[22] J. Joung,et al. High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.
[23] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.
[24] P. Renz,et al. CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells , 2015, Experimental hematology.
[25] G. Church,et al. Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.
[26] Adrian W. Briggs,et al. Stable Gene Targeting in Human Cells Using Single-Strand Oligonucleotides with Modified Bases , 2012, PloS one.
[27] B. Smart. Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome , 2011, Pediatrics.
[28] Yanpeng Wang,et al. Genome editing in rice and wheat using the CRISPR/Cas system , 2014, Nature Protocols.
[29] C. Cale,et al. Clinical Manifestations of Disease in X-Linked Carriers of Chronic Granulomatous Disease , 2013, Journal of Clinical Immunology.
[30] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[31] Adeline R. Whitney,et al. Innate Immunity against Granulibacter bethesdensis, an Emerging Gram-Negative Bacterial Pathogen , 2011, Infection and Immunity.
[32] Martin J. Aryee,et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.
[33] L. Notarangelo,et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.